The goal of the Cancer Epidemiology Program (CEP) is to improve our ability to prevent cancer and reduce its burden through new knowledge in surveillance, etiology, patterns of care, and survival, using an interdisciplinary approach. Special emphasis is placed on racial, ethnic, cultural, and other groups with an unequal burden of cancer. This research has been conducted primarily via large populationbased case-control and cohort studies in the ethnically diverse population of the San Francisco Bay Area, which includes Oakland and San Jose. Case-control studies typically collect demographic and exposure data, DNA from peripheral lymphocytes, and/or archived tumor samples. Cohort studies are based on follow-up of healthy individuals for cancer incidence (e.g., California Teachers Study), and of incident cases for cancer care, quality of life, and survival (e.g., CanCORS and Family Registries). Cancer sites of particular interest include breast, ovary, prostate, and lymphomas. This work has been facilitated and enhanced by the recent formal affiliation between Stanford University and the Northern California Cancer Center (NCCC). Some highlights of Program research include findings that oral contraceptive use is associated with reduced ovarian cancer risk and no elevation in breast cancer risk among carriers of BRCA1 mutations, that Helicobacter pylori infection is associated with reduced risk of esophageal cancer, that ethnic differences exist in use of alternative cancer therapies, and that choice of breastconserving surgery is related to socioeconomic status, immigration status and acculturation, and race/ethnicity. The Program adds value to the Cancer Center through its population-based study resources that provide a strong basis for developing important interdisciplinary collaborations and conducting translational research. Dr. Alice S. Whittemore and Dr. Esther M. John lead the Program, both senior cancer epidemiologists with extensive cancer research programs who have worked together for over 15 years. The CEP consists of 23 members, with direct cost funding of $20,220,819, including $6,463,763 in NCI funding. In the period from 2000 to the present, the average number of publications by Program members was 33 per year;of these, 40% were intra-programmatic and 14% were interprogrammatic. Future plans include expanding intra- and inter-programmatic interactions among investigators, identifying new research opportunities, and evaluating the feasibility of a data collection Shared Resource within the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-03
Application #
7826894
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
3
Fiscal Year
2009
Total Cost
$20,912
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15

Showing the most recent 10 out of 322 publications